Repros Therapeutics (RPRX +3.3%) moves higher after providing a status update for the one year open label extension of its Phase II clinical study of Androxal, an oral therapy designed to treat low testosterone in men.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs